Last reviewed · How we verify

Amneal Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief

Amneal Pharmaceuticals, LLC pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Diclofenac Sodium Topical Gel, 1% Diclofenac Sodium Topical Gel, 1% marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology
Voltaren Topical Gel, 1% Voltaren Topical Gel, 1% phase 3 NSAID COX Musculoskeletal
Vehicle Diclofenac Sodium Topical Gel Vehicle Diclofenac Sodium Topical Gel phase 3 NSAID COX-2 Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Organon and Co · 2 shared drug classes
  2. Iroko Pharmaceuticals, LLC · 2 shared drug classes
  3. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 shared drug classes
  4. Noven Pharmaceuticals, Inc. · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Apsen Farmaceutica S.A. · 1 shared drug class
  7. Antibe Therapeutics Inc. · 1 shared drug class
  8. Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amneal Pharmaceuticals, LLC:

Cite this brief

Drug Landscape (2026). Amneal Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amneal-pharmaceuticals-llc. Accessed 2026-05-16.

Related